Analysts think CPRX stock price could increase by 49%
Mar 09, 2025, 11:25 AM
-0.52%
What does CPRX do
Catalyst Pharmaceuticals, based in Coral Gables, Florida, develops and commercializes novel medicines for rare diseases, including FIRDAPSE for Lambert-Eaton Myasthenic Syndrome and AGAMREE for Duchenne Muscular Dystrophy. The company, which went public in 2006, employs 167 people.
11 analysts think CPRX stock price will increase by 48.70%. The current median analyst target is $32.64 compared to a current stock price of $21.95. The lowest analysts target is $29.29 and the highest analyst target is $42.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
